Report LibraryAll Reports
Datamonitor Healthcare CV&Met Disease Analysis: Diabetic Nephropathy
October 04, 2021
The diabetic nephropathy (DN) market is complex, because in addition to specific mechanisms that directly impact the disease, blood pressure and glycemic control are additional general targets that affect the condition. Moreover, there is high CV risk in DN patients, and many physicians may be more concerned about that than the risk for end-stage renal disease, especially in less advanced patients. Hence, drugs that directly impact DN and also benefit these other targets or have a CV benefit can have a competitive advantage.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Diabetic Nephropathy|